Since the incorporation of neurointerventional products into centralized procurement in 2021, the industry has undergone transformative changes. Product prices have plummeted, with the average price of coils diving from 12,000 yuan to roughly 3,244 yuan, and thrombectomy stents witnessing a significant drop from 26,900 yuan to below 4,000 yuan. Amidst this shift, domestic products have surged in market share, rising from less than 10% to 26%. Initially, leading firms like MicroPort Neurotech, Venus Medtech, and Perio Therapeutics grappled with losses, but by 2024, they had successfully transitioned to profitability through strategic diversification of product lines, bolstered sales, accelerated internationalization efforts, supply chain optimization, and refined management practices. These companies have witnessed rapid revenue growth, with overseas markets emerging as new engines of expansion. Meanwhile, domestic market share has further consolidated among these leading players, signaling the industry's progression into a phase of elimination and consolidation. Looking ahead, these companies are poised to further enhance operational efficiency, expand their global footprints, and bolster innovative R&D capabilities in pursuit of additional profit growth avenues.